Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is synthesized as a membrane-anchored precursor that is proteolytically cleaved to release the soluble mature growth factor, HB-EGF (1, 2). The former functions as juxtacrine and the latter as paracrine growth factor. Soluble HB-EGF shows several forms in western blotting with apparent molecular weights 19~27 kDa due to heterogeneous O-glycosylation and N-terminal truncation. HB-EGF activates EGFR and ErbB4 and promotes the development of many tissues. In human ProHB-EGF is the cellular receptor for diphtheria toxin (3). Non-toxic mutant of diphtheria toxin, CRM197, inhibit HB-EGF function, which is elevated in most ovarian cancer, is being tested as an anticancer drug (4). The hybridoma clone 4G10 was established and characterized by the members of Prof. E. Mekada of Osaka University, who is a leading scientist in this field (3, 4).
1. Western blotting (0.2~1 ug /ml)
2. Immunoprecipitation. (2 ug/ml)
3. Indirect immuno-fluorescence staining (510 ug/ml)
Samples; (Vero-H) Vero cells carrying human HG-EGF expression vector. (Vero-mH) Vero cells carrying mouse HB-EGF expression vector. Cells treated with antibody 4G10, fixed with 4% PFA and reacted with Cys3 conjugated 2nd antibody.
1. Higashiyama S. et al. Science 251: 936 (1991)
2. Prenzel N. et al. Nature 402: 884 (1999)
3. Iwamoto R. et al. EMBO J 13: 2322 (1994)
4. Miyamoto S. et al. Cancer Res. 64:5720 (2004)
To be used for research only. DO NOT use for human gene therapy or clinical diagnosis.